Pharma BD Deal Intelligence
Sanofi-Synthelabo launched a 48.5 billion-euro hostile takeover bid for Aventis (successor to Rhone-Poulenc) in a daring move to create the third-largest drugs…
Analysts said it was only a matter of time, and price, before Aventis agrees to become part of Sanofi, framing the contested bid as a question of valuation…
Sanofi-Synthelabo and Aventis agreed a friendly merger creating Sanofi-Aventis, the largest pharmaceuticals group in Europe and third largest worldwide, after…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi and Rhone-Poulenc are connected through corporate lineage rather than a direct acquisition between the two. Rhone-Poulenc merged with Hoechst in 1999 to form Aventis; in 2004, Sanofi-Synthelabo acquired Aventis -- initially through a hostile bid valued at roughly EUR 48.5 billion and ultimately agreed as a friendly merger -- to create Sanofi-Aventis, then the world's third-largest pharmaceutical group. No standalone transaction in which Sanofi acquired Rhone-Poulenc took place.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Rhône-Poulenc (this deal) | 1895 | — | 48 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 1895 deals · Sanofi SA deals · Neurology deals